trending Market Intelligence /marketintelligence/en/news-insights/trending/nw8jrntapveptqopm2q-kw2 content esgSubNav
In This List

Editas Medicine appoints former Patheon CEO as chairman

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Editas Medicine appoints former Patheon CEO as chairman

Editas Medicine, Inc. appointed James Mullen as board chairman, effective March 28.

Mullen previously served as CEO of Patheon NV until the company's acquisition by Thermo Fisher Scientific Inc.

In addition, the Cambridge, Mass.-based biotechnology company said its co-founder Alexis Borisy and John Mendlein stepped down from the company's board.

Borisy joined the board in 2013. Mendlein, who is Moderna Therapeutics Inc.'s president of corporate and product strategy, joined Editas' board in 2016.